
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SULTRIN | Johnson & Johnson | N-005794 DISCN | 1982-01-01 | 2 products |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KLARON | Bausch Health Companies | N-019931 RX | 1996-12-23 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BLEPHAMIDE | Allergan | N-012813 DISCN | 1982-01-01 | 1 products, RLD |
| METIMYD | Merck & Co | N-010210 DISCN | 1982-01-01 | 2 products |
Brand Name | Status | Last Update |
|---|---|---|
| avar | unapproved drug other | 2023-08-30 |
| avar ls | unapproved drug other | 2023-08-30 |
| avar-e | unapproved drug other | 2023-09-26 |
| avar-e green | unapproved drug other | 2025-08-12 |
| avar-e ls | unapproved drug other | 2025-08-12 |
| blephamide | New Drug Application | 2013-11-15 |
| cetamide isopto cetamide | 2006-11-20 | |
| clenia plus | unapproved drug other | 2024-07-11 |
| clindamycin 1% / sodium sulfacetamide monohydrate 5% / tretinoin 0.025% | unapproved drug other | 2019-05-03 |
| fml-s | 2007-02-20 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meibomian gland dysfunction | D000080343 | — | H02.88 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 1 | 1 |
| Neoplastic processes | D009385 | — | — | — | — | — | — | 1 | 1 |
| Pathologic processes | D010335 | — | — | — | — | — | — | 1 | 1 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | — | 1 | 1 |
| Drug common name | Sulfacetamide |
| INN | sulfacetamide |
| Description | Sulfacetamide is a sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen. It has a role as an antimicrobial agent, an antiinfective agent, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor and an antibacterial drug. It is a substituted aniline and a N-sulfonylcarboxamide. It is functionally related to a sulfanilamide. It is a conjugate acid of a sulfacetamide(1-). |
| Classification | Small molecule |
| Drug class | antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)NS(=O)(=O)c1ccc(N)cc1 |
| PDB | — |
| CAS-ID | 144-80-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL455 |
| ChEBI ID | 63845 |
| PubChem CID | 5320 |
| DrugBank | DB00634 |
| UNII ID | 4965G3J0F5 (ChemIDplus, GSRS) |

